Teniposide (Synonyms: VM26)

Name: Teniposide
Brand: MedChemExpress
SKU: HY-13761
Rating: 5.0 (13 reviews)

Cat. No.: HY-13761 Purity: 98.40%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Teniposide is a podophyllotoxin derivative, acts as a topoisomerase II inhibitor, and used as a chemotherapeutic agent.

For research use only. We do not sell to patients.

CAS No. : 29767-20-2

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	Get quote
1 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 13 publication(s) in Google Scholar

Other Forms of Teniposide:

Teniposide (Standard) Get quote

13 Publications Citing Use of MCE Teniposide

ELISA

RT-PCR

Histological Imaging/Staining

: Teniposide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]; Teniposide (10.7 μM for Hep3B cells; 26.15 μM for Huh7 cells; 24 h) significantly increased the IFN-β secretion in Hep3B and Huh7 cells.

: Teniposide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]; Teniposide (10.7 μM for Hep3B cells; 26.15 μM for Huh7 cells; 24 h) significantly increased the mRNA expression of IFIT1, IFIT2, CCL5 and CXCL10 in Hep3B and Huh7 cells.

: Teniposide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]; Teniposide (10.7 μM for Hep3B cells; 26.15 μM for Huh7 cells; 24 h) increased the cellular protein expression of p-IRF3 and p-P65 in Hep3B and Huh7 cells under normoxic conditions.

: Teniposide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]; Teniposide (Teni) (10 mg/kg; i.p.; every other day for twice) increased tumor p-IRF3 expression in mouse HCC tumor model.

: Teniposide purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]; Teniposide (Teni) (10 mg/kg; i.p.; every other day for twice)significantly increased Ifn-b, Ccl5 and Cxcl10 mRNA expression in the tumor tissues ofmouse HCC tumor model.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II DNA gyrase

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Teniposide is a podophyllotoxin derivative, acts as a topoisomerase II inhibitor, and used as a chemotherapeutic agent.

IC₅₀ & Target^[2]

Topoisomerase II

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	15.8 nM Compound: Ref 34, Cpd 3	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
A549	IC₅₀	8.2 μM Compound: Teniposide	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
CWR22R	IC₅₀	0.082 μM Compound: 3	Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide-based monolayer assay Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide-based monolayer assay	[PMID: 26854430]
HMEC	IC₅₀	12.4 μM Compound: Teniposide	Cytotoxicity against human HMEC cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HMEC cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
HeLa	ED₅₀	0.3 μg/mL Compound: 5	Cytotoxicity against human HeLa cells after 4 days by trypan blue assay Cytotoxicity against human HeLa cells after 4 days by trypan blue assay	[PMID: 1602298]
HeLa	IC₅₀	14.9 μM Compound: Teniposide	Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
HepG2	ED₅₀	40.46 mg/kg Compound: Teniposide	Antitumor activity against human HepG2 xenografted in ip dosed BALB/c nude mouse administered for 20 days and measured after 20 days by electronic caliper method Antitumor activity against human HepG2 xenografted in ip dosed BALB/c nude mouse administered for 20 days and measured after 20 days by electronic caliper method	[PMID: 32084316]
HepG2	IC₅₀	4.3 μM Compound: Teniposide	Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
HepG2	IC₅₀	62.7 μM Compound: Teniposide	Poison activity at topoisomerase-2 in human HepG2 cell lysate assessed as topoisomerase-2 band depletion after 3 hrs by Western blot analysis Poison activity at topoisomerase-2 in human HepG2 cell lysate assessed as topoisomerase-2 band depletion after 3 hrs by Western blot analysis	[PMID: 32084316]
L02	IC₅₀	11.5 μM Compound: Teniposide	Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
MCF7	IC₅₀	0.125 μM Compound: 3	Antiproliferative activity against human MCF7 cells after 96 hrs by propidium iodide-based monolayer assay Antiproliferative activity against human MCF7 cells after 96 hrs by propidium iodide-based monolayer assay	[PMID: 26854430]
MCF7	IC₅₀	11.1 μM Compound: Teniposide	Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
MCF7	IC₅₀	15.8 nM Compound: Ref 34, Cpd 3	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
MRC5	IC₅₀	12.2 μM Compound: Teniposide	Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32084316]
PC-3	IC₅₀	15.8 nM Compound: Ref 34, Cpd 3	Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
RPMI 8402	IC₅₀	0.22 μM Compound: VM-26	Cytotoxicity against human lymphoblast tumor cell line RPM18402 Cytotoxicity against human lymphoblast tumor cell line RPM18402	[PMID: 12392745]
RPMI 8402	IC₅₀	0.22 μM Compound: VM-26	Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment	[PMID: 12747798]
RPMI 8402	IC₅₀	0.28 μM Compound: VM-26	Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-1 Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-1	[PMID: 12392745]

In Vitro

Teniposide is a topoisomerase II inhibitor. Teniposide (VM-26, 0.15-45 mg/L) inhibits the proliferation of Tca8113 cells in a dose-dependent manner, with an IC₅₀ of 0.35 mg/L. Teniposide (5 mg/L) induces apoptosis of Tca8113 cells. Teniposide (5.0 mg/L) causes cell arrested at G2/M phase in Tca8113 cells^[2]. Teniposide is active on primary cultured glioma cells from patients, when the level of miR-181b is high in the cells, with an IC₅₀ of 1.3 ± 0.34 μg/mL. Cells treated with teniposide with low MDM2 have decreased viability compared with control cells, and the IC₅₀ decreases from 5.86 ± 0.36 μg/mL to 2.90 ± 0.35 μg/mL upon MDM2 suppression. Teniposide also inhibits the viability of glioma cell with high level of miR-181b, through mediation of MDM2^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Teniposide (0.5 mg/kg, i.p.) significantly increases micronucleated polychromatic erythrocyte (MNPCE) frequencies, which is directly related to bone marrow toxicity as significant suppression of bone marrow is noted. Teniposide (24 mg/kg, i.p.) markedly decreases the frequencies of BrdU-labelled sperm. Teniposide (12, 24 mg/kg, i.p.) also dramatically induces disomic sperm in the germ cell of male mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

656.65

Formula

C₃₂H₃₂O₁₃S

CAS No.

29767-20-2

Appearance

Solid

Color

White to off-white

SMILES

O=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO4)O3)O[C@@H]4C5=CC=CS5)O)O)C6=C(C=C7OCOC7=C6)[C@@H](C8=CC(OC)=C(O)C(OC)=C8)[C@]21[H]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : ≥ 30 mg/mL (45.69 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.5229 mL	7.6144 mL	15.2288 mL
5 mM	0.3046 mL	1.5229 mL	3.0458 mL
10 mM	0.1523 mL	0.7614 mL	1.5229 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.00%

Select Batch:

Data Sheet (290 KB) SDS (418 KB)

COA (265 KB) HNMR (117 KB) RP-HPLC (281 KB)

Handling Instructions (2659 KB)

References

[1]. Attia SM, et al. Molecular cytogenetic evaluation of the aneugenic effects of teniposide in somatic and germinal cells of male mice. Mutagenesis. 2012 Jan;27(1):31-9. [Content Brief]

[2]. Li J, et al. Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma. World J Surg Oncol. 2006 Jul 6;4:41. [Content Brief]

[3]. Sun YC, et al. MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer. 2014 Aug 25;14:611. [Content Brief]

Cell Assay ^[2]	Logarithmically growing Tca8113 cells are trypsinized and made into single cell suspension then plated in 96-well culture plate at a concentration of 5 × 10⁴ cells/well, eight columns for Teniposide and seven columns for CDDP in each plate, 3 wells in each column. After 24 hours of incubation, the medium of the 3 wells in each column are replaced with medium containing Teniposide of 0.15 mg/L, 0.5 mg/L, 1.5 mg/L, 5.0 mg/L, 15 mg/L and 45 mg/L or CDDP of 0.1 mg/L, 0.3 mg/L, 1.0 mg/L, 3.0 mg/L and 9.0 mg/L, respectively. Blank control wells are added medium without drugs. Cells are then cultured for another 24 hours, 48 hours, 72 hours, 96 hours and 120 hours. The supernatants are removed and 20 μL MTT solution is added in each well, followed with another 4 hours of culture. The supernatants are discarded carefully and 200 μL dimethyl sulphoxide (DMSO) is added and shaken vigorously to dissolve the purple precipitation formation. Optical density (OD) of each well is tested using Spectrophotometer with a wavelength of 450 nm. The experiment is repeated in triplicate^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Animals (mice) are treated with 0.5 mg/kg teniposide and bone marrow is sampled 24 h after treatment. Colchicine and mitomycin C are used as a positive control aneugen and clastogen, respectively, at the dose of 2 mg/kg each. Bone marrow smears are prepared and stained with May-Gruenwald/Giemsa solutions. At least four slides are made for each animal and allowed to dry overnight. One slide per animal is stained with May-Gruenwald/Giemsa solutions for conventional assessment of the micronuclei (MN) frequencies in polychromatic erythrocytes (PCEs) and normochromatic erythrocytes (NCEs). The remaining unstained slides are stored at −20°C for the distinction between the clastogenic and aneugenic effects by identifying the origin of MN with the mouse DNA probes. Per animal, 1000 PCE of coded slides are scored for the presence of MN. In addition, the number of PCEs among 1000 NCE per animal is recorded to evaluate bone marrow suppression and mitotic activity is calculated as %PCE = [PCE/(PCE + NCE)] × 100^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Attia SM, et al. Molecular cytogenetic evaluation of the aneugenic effects of teniposide in somatic and germinal cells of male mice. Mutagenesis. 2012 Jan;27(1):31-9. [Content Brief] [2]. Li J, et al. Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma. World J Surg Oncol. 2006 Jul 6;4:41. [Content Brief] [3]. Sun YC, et al. MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer. 2014 Aug 25;14:611. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.5229 mL	7.6144 mL	15.2288 mL	38.0720 mL
	5 mM	0.3046 mL	1.5229 mL	3.0458 mL	7.6144 mL
	10 mM	0.1523 mL	0.7614 mL	1.5229 mL	3.8072 mL
	15 mM	0.1015 mL	0.5076 mL	1.0153 mL	2.5381 mL
	20 mM	0.0761 mL	0.3807 mL	0.7614 mL	1.9036 mL
	25 mM	0.0609 mL	0.3046 mL	0.6092 mL	1.5229 mL
	30 mM	0.0508 mL	0.2538 mL	0.5076 mL	1.2691 mL
	40 mM	0.0381 mL	0.1904 mL	0.3807 mL	0.9518 mL

Teniposide Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Teniposide29767-20-2VM26VM 26VM-26TopoisomeraseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Teniposide (Synonyms: VM26)

Customer Review

Other Forms of Teniposide:

Teniposide Related Antibodies

13 Publications Citing Use of MCE Teniposide

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Teniposide Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Teniposide Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report